Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Calabrese, J. R. Articles by Findling, R. L. Search for Related Content PubMed Citation Articles by Calabrese, J. R. Articles by Findling, R. L. Bipolar Disorder Lithium Related Article

A 20-Month, Double-Blind, Maintenance Trial of Lithium Versus Divalproex in Rapid-Cycling Bipolar Disorder

OBJECTIVE: The authors tested the hypothesis that divalproex would be more effective than lithium in the long-term management of patients with recently stabilized rapid-cycling bipolar disorder. METHOD: A 20-month, double-blind, parallel-group comparison was carried out in recently hypomanic/manic patients who had experienced a persistent bimodal response to combined treatment with lithium and divalproex. Sixty patients were randomly assigned to lithium or divalproex monotherapy in a balanced design after stratification for illness type (bipolar I versus bipolar II disorder). RESULTS: Of the 254 patients enrolled in the open-label acute stabilization phase, 76% discontinued the study prematurely (poor adherence: 28%; nonresponse: 26% [of whom 74% remained depressed and 26% remained in a hypomanic/manic/mixed episode], intolerable side effects: 19%). Of the 60 patients (24%) randomly assigned to double-blind maintenance monotherapy, 53% relapsed (59% into depression and 41% into a hypomanic/manic/mixed episode), 22% completed the study, 10% had intolerable side effects, and 10% were poorly adherent. The rates of relapse into any mood episode for those given lithium versus divalproex were 56% and 50%, respectively; the rates were 34% and 29% for a depressive relapse and 19% and 22% for a hypomania/mania relapse. There were no significant differences in time to relapse. The proportion discontinuing prematurely because of side effects was 16% for lithium and 4% for divalproex. CONCLUSIONS: The hypothesis that divalproex is more effective than lithium in the long-term management of rapid-cycling bipolar disorder is not supported by these data. Preliminary data suggest highly recurrent refractory depression may be the hallmark of rapid-cycling bipolar disorder.

Related Article:

In This Issue
Am J Psychiatry 2005 162: A56. [Full Text] [PDF]

This article has been cited by other articles:

				S Beynon, K Soares-Weiser, N Woolacott, S Duffy, and J. Geddes Pharmacological interventions for the prevention of relapse in bipolar disorder: a systematic review of controlled trials J Psychopharmacol, July 1, 2009; 23(5): 574 - 591. [Abstract] [PDF]

				M. Sajatovic, K. Biswas, A. K. Kilbourne, H. Fenn, W. Williford, and M. S. Bauer Factors Associated With Prospective Long-Term Treatment Adherence Among Individuals With Bipolar Disorder Psychiatr Serv, July 1, 2008; 59(7): 753 - 759. [Abstract] [Full Text] [PDF]

				S. N. Ghaemi Treatment of Rapid-Cycling Bipolar Disorder: Are Antidepressants Mood Destabilizers? Am J Psychiatry, March 1, 2008; 165(3): 300 - 302. [Full Text] [PDF]

				A. Capetti, S. Landonio, I. Faggion, and G. Rizzardini Drop in Plasma Lithium Levels in 2 Patients on Concomitant Boosted Protease Inhibitor Regimens J Int Assoc Physicians AIDS Care (Chic Ill), September 1, 2006; 5(3): 119 - 120. [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2005 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us